Drugs / foselutoclax
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04537884 | Oct 2020 → Jan 2022 | diabetic macular edema, wet macular degeneration | Unity Biotechnology, Inc. | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT06011798 | Aug 2023 → Jan 2025 | diabetes mellitus, diabetic macular edema, macular retinal edema | Unity Biotechnology, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT05275205 | Mar 2022 → Feb 2023 | wet macular degeneration | Unity Biotechnology, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT04857996 | Jun 2021 → Apr 2023 | diabetic macular edema | Unity Biotechnology, Inc. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | foselutoclax | “BACKGROUND: We tested the ability of a single intravitreal injection of foselutoclax (hereafter UBX1325), a novel senolytic small molecule inhibitor of antiapoptotic protein...” PMID 40261111 ↗ Apr 20252“UBX1325 (foselutoclax), a senolytic small-molecule inhibitor of BCL-xL” PMID 38321220 ↗ Feb 2024 |
| Known as | UBX1325 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04857996 ↗ |
| Action | Inhibit | “inhibitor of BCL-xL” PMID 38321220 ↗ Feb 2024 |
| Modality | Small molecule | “a senolytic small-molecule inhibitor” PMID 38321220 ↗ Feb 2024 |
| Route | Intravitreal | “single intravitreal injection” NCT04537884 ↗ |